Detailed instructions for avatrombopag tablets

Avatrombopag is an oral, small-molecule thrombopoietin receptor agonist, mainly used to treat preoperative thrombocytopenia in patients with chronic liver disease and chronic immune thrombocytopenia (ITP). The drug stimulates megakaryocytes in the bone marrow to produce platelets, effectively increasing the number of platelets and thus reducing the risk of bleeding. The following is a detailed introduction to the instructions for avatrombopag tablets, including its indications, usage and dosage, adverse reactions, contraindications and precautions.

1. Indications and mechanisms

Avatrombopag is suitable for the treatment of two major categories of diseases. One is that patients with chronic liver disease (CLD) have thrombocytopenia before undergoing invasive operations, which is used to increase platelets to reduce the risk of intraoperative bleeding. The second is for the treatment of adult patients with chronic immune thrombocytopenia (ITP). These patients have long-term low platelets and are at risk of bleeding. Avatrombopag can help increase platelet levels and maintain them within a safe range.

The drug’s mechanism of action is to activate the thrombopoietin receptor (TPO-R), promote the maturation and differentiation of megakaryocytes in the bone marrow, and thereby increase the production of platelets. Compared with other similar drugs, avatrombopag has the characteristics of good oral absorption, rapid onset of action, and less impact on liver enzyme levels. It has good clinical safety and compliance.

2. Usage and dosage

Avatrombopag is an oral preparation and is generally taken once daily. It is recommended to take it with or after a meal to enhance absorption. Dosages vary for different indications:

For preoperative use in patients with chronic liver disease: Depending on the baseline platelet count, the recommended dose is one tablet per day (40mg) or two tablets per day (80mg), take it for five consecutive days, and schedule surgery on the 5th to 8th day.

When used in patients with chronic ITP: The starting dose is usually 20mg once a day, and the dose can be adjusted according to the patient's platelet response, with a maximum of no more than 40mg per day.

Platelet count needs to be monitored regularly during medication to avoid the risk of thrombosis caused by excessive platelet elevation. If the platelet count is higher than the upper limit of normal, discontinuation or dose reduction should be considered.

3. Adverse reactions and safety

Clinical studies and post-marketing surveillance have shown that avatrombopag is well tolerated, but there is still a certain risk of side effects. Common adverse reactions include:

Headache: One of the most commonly reported symptoms of discomfort, usually mild or moderate.

Fatigue, nausea, and abdominal pain: may be related to slight gastrointestinal tract irritation or drug metabolism.

Risk of thrombosis: Because the drug increases the number of platelets, some high-risk patients may develop thrombotic events, such as deep vein thrombosis, pulmonary embolism, etc.

Abnormal liver function: Although rare, periodic monitoring of liver enzymes during treatment is recommended.

Overall, the side effects of avatrombopag are controllable, most are mild to moderate, and can be relieved after stopping the drug or adjusting the dose.

4. Taboos and Precautions

Avatrombopag is contraindicated in patients who are allergic to its active ingredient or any of its excipients. Special attention should be paid to the following matters during use:

1.Pregnant and lactating women: Due to the lack of sufficient human trial data, pregnant and lactating women are not recommended to use this drug unless the potential benefits outweigh the risks.

2.Pediatric Medication: At present, clear safety and effectiveness have not been established in children under 18 years old, and use by children is not recommended.

3.Patients with hepatic insufficiency: For patients with significantly impaired liver function, medication should be used with caution and close observation should be conducted.

4.Combination medication: Avoid combination with other drugs that affect platelets, such as anticoagulants and antiplatelet drugs, to reduce the risk of bleeding or thrombotic complications.

5. Storage and drug information

Avatrombopag should be stored in a cool, dry place away from high temperature, moisture and direct sunlight. It should be kept out of the reach of children to avoid accidental ingestion. The drug specifications are usually packaged in 20mg or 40mg packaging. When using, the dosage should be carried out according to the doctor's prescription and cannot be increased or decreased at will.

In summary, avatrombopag, as a new oral platelet-raising drug, has shown good efficacy and safety in the treatment of thrombocytopenia, especially chronic liver disease andITP. Patients should use medications rationally under the guidance of professional doctors and regularly monitor relevant indicators to ensure maximum treatment effects and reduce the risk of adverse reactions.

Reference materials:https://go.drugbank.com/drugs/DB11995